Overview

Gender

male

Robert Blanks has over 20 years of experience in the pharmaceutical industry in the Quality, Regulatory and CMC areas. A majority of this experience has been with small biotech companies, where he has played a critical role in developing companies’ initial drug product candidates, including peptides, monoclonal antibodies and small molecules, from the pre-clinical stage to commercial registration.

He was most recently at Flexion Therapeutics as Vice President of CMC, where he oversaw the development of the company’s initial two drug product candidates, which recently completed successful phase 2 studies.

Prior to Flexion, he was Vice President of Quality at Idenix Pharmaceuticals overseeing all quality aspects of the commercial launch of the company’s first product, Tyzeka®.

Previous to Idenix, he served as Vice President of Technical Operations for Trine Pharmaceuticals and Vice President of Technical Operations and Founder of Phaedrus Pharmaceuticals. At GelTex Pharmaceuticals, subsequently purchased by Genzyme, he was a key participant in both the quality and regulatory areas in the development and registration of RenaGel®.

Mr. Blanks has a BS in Biology from Bowdoin College and a MS in Chemistry from Boston College. Mr. Blanks is Regulatory Affairs Certified.